Final answer:
Reopro, Integrilin, and Aggrastat are platelet aggregation inhibitors targeting the glycoprotein IIb/IIIa receptor, preventing blood clots. They differ from Candesartan, Eprosartan, and Irbesartan, which are Angiotensin II Receptor Blockers used to manage hypertension by causing vasodilation.
Step-by-step explanation:
Reopro, Integrilin, and Aggrastat are medications that act as platelet aggregation inhibitors. These drugs block the action of specific receptors involved in the process of platelet aggregation, which is a crucial step in blood clot formation. Specifically, Reopro is an antibody that blocks the glycoprotein IIb/IIIa receptor on the platelet surface, Integrilin is a small molecule that inhibits the same receptor, and Aggrastat is an antagonist of the glycoprotein IIb/IIIa receptor as well. These medications are used to prevent blood clots in patients who are at high risk of developing thrombotic cardiovascular events such as during percutaneous coronary intervention (PCI).
Candesartan (Atacand), Eprosartan (Teveten), and Irbesartan (Avapro) are examples of Angiotensin II Receptor Blockers (ARBs). These widely prescribed medications work by blocking the action of angiotensin II, a potent vasoconstrictor, thereby leading to vasodilation and a reduction in blood pressure. ARBs are commonly used for treating hypertension and other cardiovascular conditions.